---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008110"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:29:48.934243+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Omeros Q1 net loss $33.0M ($0.53/shr); OMIDRIA royalties $13.8M; preparing FDA dispute resolution

## Summary
- Net loss of $33.0M ($0.53/shr) vs $35.1M ($0.57) in Q1 2021; non-cash items $4.2M.
- Royalty revenue of $13.8M from Rayner's OMIDRIA sales ($27.7M, all U.S.); up from $21.1M prior Omeros net sales.
- Cash, equivalents, short-term investments $142.2M at March 31, 2022; down $15M from Dec 2021.
- FDA denied narsoplimab BLA (TA-TMA); Omeros plans formal dispute resolution within weeks.
- Enrollment expected summer 2022 for Phase 1b OMS906 (PNH) and Phase 1 OMS1029 (long-acting MASP-2).

## SEC filing metadata
- accession: 0001558370-22-008110
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/0001558370-22-008110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837022008110/omer-20220510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008110
- JSON: https://secwatch.observer/filing/0001558370-22-008110.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.